MZ-101

• UNSPSC Description:

  MZ-101 (GYS1-IN-2) is an orally active, potent and selective small-molecule glycogen synthase 1 (GYS1) inhibitor with with an IC50 value of 0.041 µM. MZ-101 reduces glycogen concentrations in cells and in mice. MZ-101 can used to study GYS1 -mediated Pompe disease and other glycogen storage diseases[1][2][3].

• Target Antigen:

  Others

• Type:

  Reference compound

• Related Pathways:

  Others

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/mz-101.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C([C@H]1N(C[C@@H](C1)F)C(CC2=CN=NN2)=O)N[C@@H](C3=CC=CC=C3)C4=CC=C(C=C4)C(C)C

• Molecular Weight:

  449.52

• References & Citations:

  [1]David John Morgans, et al. Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof. WO2022198196. 2022-09-22.|[2]Ullman JC, et al. Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders. Sci Transl Med. 2024 Jan 17;16(730):eadf1691.|[3]Gaspar RC, et al. Small molecule inhibition of glycogen synthase I reduces muscle glycogen content and improves biomarkers in a mouse model of Pompe disease. Am J Physiol Endocrinol Metab. 2024 Oct 1;327(4):E524-E532.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2839908-40-4